Table 2.
The results of a multivariate analysis regarding the association between ADAMTS13 variations and clinical outcomes after transplantation.
| Variable | n | Adjusted 3-y DFS | HR (95% CI) | P | Adjusted 3-y OS | HR (95% CI) | P | Adjusted 3-y Relapse | HR (95% CI) | P |
| Overall | 281 | 61% | 63% | 18% | ||||||
| Recipient ADAMTS13, C/C | 206 | 58% | 1.64 (1.01–2.67) | 0.045 | 61% | 1.40 (0.86–2.29) | 0.180 | 21% | 3.12 (1.25–7.77) | 0.015 |
| Recipient ADAMTS13, C/T or T/T | 75 | 71% | 71% | 13% | ||||||
| Donor ADAMTS13, C/C | 203 | 60% | 1.18 (0.74–1.89) | 0.489 | 62% | 1.23 (0.76–2.01) | 0.403 | 20% | 1.26 (0.60–2.66) | 0.550 |
| Donor ADAMTS13, C/T or T/T | 78 | 66% | 67% | 14% | ||||||
| Variable | n | Adjusted 3-y NRM | HR (95% CI) | P | Adjusted grades 2–4 acute GVHD | HR (95% CI) | P | Adjusted chronic GVHD | HR (95% CI) | P |
| Overall | 281 | 23% | 34% | 28% | ||||||
| Recipient ADAMTS13, C/C | 206 | 23% | 1.03 (0.55–1.94) | 0.920 | 35% | 1.08 (0.64–1.81) | 0.770 | 28% | 1.00 (0.57–1.73) | 0.990 |
| Recipient ADAMTS13, C/T or T/T | 75 | 25% | 32% | 27% | ||||||
| Donor ADAMTS13, C/C | 203 | 24% | 1.03 (0.55–1.91) | 0.930 | 34% | 0.93 (0.58–1.49) | 0.750 | 27% | 0.74 (0.46–1.22) | 0.240 |
| Donor ADAMTS13, C/T or T/T | 78 | 22% | 34% | 33% |
DFS, disease-free survival; HR, hazard ratio; OS, overall survival; CI, confidence interval; NRM, non-relapse mortality. Bolded results regarding the genotype represent P < 0.05.